Recent advances in pharmacogenomics technologies allow bold steps to be taken towards personalized medicine, more accurate health planning, and personalized drug development. In this framework, systems pharmacology network-based approaches offer an appealing way for integrating multi-omics data and set the basis for defining systems-level drug response biomarkers. On the road to individualized tamoxifen treatment in estrogen receptor-positive breast cancer patients, we examine the dynamics of the attendant pharmacological response mechanisms. By means of an “integromics” network approach, we assessed the tamoxifen effect through the way the high-order organization of interactome (i.e., the modules) is perturbed. To accomplish that, first we integrated the time series transcriptome data with the human protein interaction data, and second, an efficient module-detecting algorithm was applied onto the composite graphs. Our findings show that tamoxifen induces severe modular transformations on specific areas of the interactome. Our modular biomarkers in response to tamoxifen attest to the immunomodulatory role of tamoxifen, and further reveal that it deregulates cell cycle and apoptosis pathways, while coordinating the proteasome and basal transcription factors. To the best of our knowledge, this is the first report that informs the fields of personalized medicine and clinical pharmacology about the actual dynamic interactome response to tamoxifen administration.
Get full access to this article
View all access options for this article.
References
1.
AhnJ, YoonY, ParkC, ShinE, and ParkS. (2011). Integrative gene network construction for predicting a set of complementary prostate cancer genes. Bioinformatics, 27, 1846–1853.
2.
AntmanE, WeissS, and LoscalzoJ. (2012). Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med, 4, 367–383.
3.
AkmanBH, CanT, and Erson-BensanAE. (2012). Estrogen-induced upregulation and 3'-UTR shortening of CDC6. Nucleic Acids Res, 40, 10679–10688.
4.
BeckerM, SommerA, KrätzschmarJR, SeidelH, PohlenzHD, and FichtnerI. (2005). Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther, 4, 151–168.
5.
BergerSI, and IyengarR. (2009). Network analyses in systems pharmacology. Bioinformatics, 25, 2466–2472.
6.
BehjatiS, and FrankMH. (2009). The effects of tamoxifen on immunity. Curr Med Chem, 16, 3076–3080.
7.
BertucciF, FinettiP, CerveraN, et al. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res, 66, 4636–4644.
8.
BonteD, LindvallC, LiuH, DykemaK, FurgeK, and WeinreichM. (2008). Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia, 10, 920–931.
9.
ChenD, Landis-PiwowarKR, ChenMS, and DouQP. (2007). Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res, 9, R80.
10.
ChenL, XuanJ, RigginsRB, WangY, and ClarkeR. (2013). Identifying protein interaction subnetworks by a bagging Markov random field-based method. Nucleic Acids Res, 41, e42.
11.
ChuangHY, LeeE, LiuYT, LeeD, and IdekerT. (2007). Network-based classification of breast cancer metastasis. Mol Syst Biol, 3, 140.
12.
CouchRD, and MottBT. (2012). Personalized medicine: Changing the paradigm of drug development. Methods Mol Biol, 823, 367–378.
13.
CunY, and FröhlichHF. (2012). Prognostic gene signatures for patient stratification in breast cancer: Accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions. BMC Bioinformat, 13, 69.
14.
DimitrakopoulouK, DimitrakopoulosG, ZacharakiEI, MaraziotisIA, SgarbasK, and BezerianosA. (2012). Revealing the dynamic modularity of composite biological networks in breast cancer treatment. Conf Proc IEEE Eng Med Biol Soc, 2012, 5432–5436.
15.
DuffyMJ, O'DonovanN, and CrownJ. (2011). Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev, 37, 151–159.
16.
FengC, ChenL, LiW, et al. (2012). Identifying grade/stage-related active modules in human co-regulatory networks: A case study for breast cancer. OMICS, 16, 681–689.
17.
FredlundE, StaafJ, RantalaJK, KallioniemiO, BorgA, and RingnérM. (2012). The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res, 14, R113.
18.
FröhlichH. (2011). Network based consensus gene signatures for biomarker discovery in breast cancer. PLoS One, 6, e25364.
19.
GentlemanRC, CareyVJ, BatesDM, et al. (2004). Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol, 5, R80.
20.
GeorgiiE, DietmannS, UnoT, PagelP, and TsudaK. (2009). Enumeration of condition-dependent dense modules in protein interaction networks. Bioinformatics, 25, 933–940.
21.
GoingJJ, KeithWN, NeilsonL, StoeberK, StuartRC, and WilliamsGH. (2002). Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut, 50, 373–377.
22.
HeckerM, LambeckS, ToepferS, van SomerenE, and GuthkeR. (2009). Gene regulatory network inference: Data integration in dynamic models—A review. BioSystems, 96, 86–103.
23.
HegdeSR, ManimaranP, and MandeSC. (2008). Dynamic changes in protein functional linkage networks revealed by integration with gene expression data. PLoS Comput Biol, 4, e1000237.
24.
HonmaN, HoriiR, IwaseT, et al. (2008).Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol, 26, 3727–3734.
25.
Horner-GlisterE, Maleki-DizajiM, GuerinCJ, JohnsonSM, StylesJ, and WhiteIN. (2005). Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol, 35, 421–432.
26.
HuangDW, ShermanBT, and LempickiRA. (2009). Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc, 4, 44–57.
27.
JahidMJ, and RuanJ. (2012). A Steiner tree-based method for biomarker discovery and classification in breast cancer metastasis. BMC Genom, 13, S8.
28.
JavierreBM, Rodriguez-UbrevaJ, Al-ShahrourF, et al. (2011). Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res, 9, 1139–1151.
29.
JohanssonI, AaltonenKE, EbbessonA, et al. (2012). Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer, 51, 375–383.
30.
JørgensenJT. (2011). A challenging drug development process in the era of personalized medicine. Drug Discov Today, 16, 891–897.
31.
KangJM, ParkS, KimSJ, et al. (2012). CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling. Oncogene, 31, 5123–5131.
32.
KomurovK, TsengJT, MullerM, et al. (2012). The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol, 8, 596.
33.
KuoCC, LiuJF, ShiahHS, MaLC, and ChangJY. (2007). Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells. Int J Cancer, 121, 2293–2300.
34.
LabibK, TerceroJA, and DiffleyJF. (2000). Uninterrupted MCM2-7 function required for DNA replication fork progression. Science, 288, 1643–1647.
35.
LiJ, LenferinkAE, DengY, et al. (2010). Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun, 1, 34.
36.
LordCJ, and AshworthA. (2012). The DNA damage response and cancer therapy. Nature, 481, 287–294.
37.
LuWJ, DestaZ, and FlockhartDA. (2012). Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat, 131, 473–481.
38.
LuWJ, XuC, PeiZ, MayhoubAS, CushmanM, and FlockhartDA. (2012). The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat, 133, 99–109.
MaraziotisIA, DimitrakopoulouK, and BezerianosA. (2007). Growing functional modules from a seed protein via integration of protein interaction and gene expression data. BMC Bioinformat, 8, 408.
41.
MaraziotisIA, DimitrakopoulouK, and BezerianosA. (2008). An in silico method for detecting overlapping functional modules from composite biological networks. BMC Syst Biol, 2, 93.
42.
MatsuyoshiS, ShimadaK, NakamuraM, IshidaE, and KonishiN. (2006). FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br J Cancer, 94, 532–539.
43.
McGovernSL, QiY, PusztaiL, SymmansWF, and BuchholzTA. (2012). Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res, 14, R72.
44.
Mendes-PereiraAM, SimsD, DexterT, et al. (2012). Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA, 109, 2730–2735.
45.
MeyerUA, ZangerUM, and SchwabM. (2013). Omics and drug response. Annu Rev Pharmacol Toxicol, 53, 475–502.
46.
MihalikÁ, and CsermelyP. (2011). Heat shock partially dissociates the overlapping modules of the yeast protein-protein interaction network: A systems level model of adaptation. PLoS Comput Biol, 7, e1002187.
47.
MorG, KohenF, Garcia-VelascoJ, et al. (2000). Regulation of fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol, 73, 185–194.
48.
MoraA, and DonaldsonIM. (2012). Effects of protein interaction data integration, representation and reliability on the use of network properties for drug target prediction. BMC Bioinformat, 13, 294.
49.
MoreiraPI, CustódioJ, MorenoA, OliveiraCR, and SantosMS. (2006). Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem, 281, 10143–10152.
50.
MutarelliM, CicatielloL, FerraroL, et al. (2008). Time-course analysis of genome-wide gene expression data from hormone-responsive human breast cancer cells. BMC Bioinformat, 9, S12.
51.
NiidaA, SmithAD, ImotoS, AburataniH, ZhangMQ, and AkiyamaT. (2009). Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinformat, 10, 71.
52.
PinkertS, SchultzJ, and ReichardtJ. (2010). Protein interaction networks—More than mere modules. PLoS Comput Biol, 6, e1000659.
53.
PollokS, BauerschmidtC, SängerJ, NasheuerHP, and GrosseF. (2007). Human Cdc45 is a proliferation-associated antigen. FEBS J, 274, 3669–3684.
54.
RossinEJ, LageK, RaychaudhuriS, et al. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet, 7, e1001273.
55.
SalazarMD, RatnamM, PatkiM, et al. (2011). During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein. Breast Cancer Res, 13, R18.
56.
ScardoniG, PetterliniM, and LaudannaC. (2009). Analyzing biological network parameters with CentiScaPe. Bioinformatics, 25, 2857–2859.
57.
SchwabM, and SchaeffelerE. (2012). Pharmacogenomics: A key component of personalized therapy. Genome Med, 4, 93.
58.
ShannonP, MarkielA, OzierO, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
59.
SharanR, UlitskyI, and ShamirR. (2007). Network-based prediction of protein function. Mol Syst Biol, 3, 88.
60.
ShihYK, and ParthasarathyS. (2012). Identifying functional modules in interaction networks through overlapping Markov clustering. Bioinformatics, 28, i473–i479.
61.
TaylorIW, LindingR, Warde-FarleyD, et al. (2009). Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol, 27, 199–204.
62.
TaylorKJ, SimsAH, LiangL, et al. (2010). Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res, 12, R39.
63.
UlitskyI, and ShamirR. (2009). Identifying functional modules using expression profiles and confidence-scored protein interactions. Bioinformatics, 25, 1158–1164.
64.
vanVlietMH, KlijnCN, WesselsLF, and ReindersMJ. (2007). Module-based outcome prediction using breast cancer compendia. PLoS One, 2, e1047.
65.
WakefieldA, SoukupovaJ, MontagneA, et al. (2013). Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res, 73, 745–755.
66.
WangJ, ChenG, LiM, and PanY. (2011). Integration of breast cancer gene signatures based on graph centrality. BMC Syst Biol, 5, S10.
67.
WangX, WangZ, and YeJ. (2011). HKC: An algorithm to predict protein complexes in protein-protein interaction networks. J Biomed Biotechnol, 2011, 480294.
68.
WarsowG, GreberB, FalkSS, et al. (2010). ExprEssence—Revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst Biol, 4, 164.
69.
WuC, ZhuJ, and ZhangX. (2012). Integrating gene expression and protein–protein interaction network to prioritize cancer-associated genes. BMC Bioinformat, 13, 182.
70.
WuG, and SteinL. (2012). A network module-based method for identifying cancer prognostic signatures. Genome Biol, 13, R112.
71.
WuZ, ZhaoX, and ChenL. (2009). Identifying responsive functional modules from protein-protein interaction network. Mol Cells, 27, 271–277.
72.
WuX, SubramaniamM, GrygoSB, et al. (2011). Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res, 13, R27.
73.
ZengT, WangR, and ChenL. (2012). Module network rewiring in response to therapy. IEEE 6th International Conference on Systems Biology (ISB), 18-20Aug2012, 197–202.
74.
ZhangJ, XiangY, DingL, et al. (2010). Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. BMC Bioinformat, 11, S5.
75.
ZhaoS, and IyengarR. (2012). Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol, 52, 505–521.
76.
ZhouC, ZhongQ, RhodesLV, et al. (2012). Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res, 14, R45.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
